Peter Lynch fit · Growth at a reasonable price (GARP)
Is Esperion Therapeutics, Inc. (ESPR) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
0/100
FNo encaja
1/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a ESPR
PEG ≤ 1.0
clave—
EPS CAGR ≥ 15%
clave-45.4%
Revenue CAGR ≥ 10%
-12.9%
Net margin > 0
-34.8%
Cómo se valora ESPR en otras estrategias
Datos financieros en vivo
Cap. mercado
$626.17M
PER (TTM)
-
ROIC (TTM)
26.87%
Margen bruto
53.54%
Preguntas frecuentes
What is ESPR's Peter Lynch fit score?
ESPR scores 0/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own ESPR?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ESPR.
How often is this score updated?
ESPR's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende ESPR personalmente.